- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
ACCC Statement on Trump Administration's Executive Orders Addressing Prescription Drug Cost
ACCC urges the administration to move carefully and with a clear understanding of the potential ramifications on the cancer care delivery infrastructure.
The Association of Community Cancer Centers (ACCC) is the leading education and advocacy organization for the cancer care community, representing more than 25,000 multidisciplinary practitioners from every discipline in oncology. Working in 2,100 private practices to hospital-based cancer programs, large healthcare systems, and major academic centers nationwide, ACCC members address the most critical issues in quality cancer care delivery.
On July 24, 2020, President Trump signed 4 Executive Orders (EOs) intended to lower prescription drug prices. While ACCC acknowledges the effort of the Trump Administration to address rising drug costs, we urge the administration to move carefully and with a clear understanding of the potential ramifications of these EOs on the cancer care delivery infrastructure.
Of particular concern is the policy that ties Medicare payment for outpatient drugs to international prices. If implemented without broader payment reform and over an extended period of time, this policy could have a devastating impact on cancer programs across the country.
AI in Health Care: Balancing Governance, Innovation, and Trust
September 2nd 2025In this conversation with Reuben Daniel, associate vice president of artificial intelligence at UPMC Health Plan, we dive into how UPMC Health Plan builds trust with providers and members, discuss challenges of scaling AI effectively, and hear about concrete examples of AI's positive impact.
Listen
Impact of Amivantamab-Lazertinib on EGFR, MET Resistance Alterations in NSCLC: Danny Nguyen, MD
September 15th 2025The combination of amivantamab and lazertinib in first-line non–small cell lung cancer (NSCLC) significantly reduces resistance mechanisms with implications for second-line treatment, said Danny Nguyen, MD, of City of Hope.
Read More
